Overview
Respiratory syncytial virus (RSV) is increasingly recognized as a key source of respiratory illness in older adults. In a 2022 Call to Action, the National Foundation for Infectious Diseases (NFID) noted approximately 177,000 RSV-related hospitalizations each year in older adults, adding that patients ages 65 and older carry a much larger RSV-associated mortality burden than do children. Continuing education that brings clinicians on the front lines of preventative primary care up to speed on RSV immunization recommendations for adults and strategies for increasing vaccination rates in this population can contribute to an improved rate of coverage—and ultimately fewer adverse respiratory outcomes.
This course is brought to you in partnership with our sister company freeCME. Clicking the Add to Cart button will take you to the freeCME website where you can access this course for FREE.
Goals and Learning Outcomes
Upon completion of this activity, participants should be better able to:
- Summarize key aspects of current ACIP recommendations for RSV vaccinations in older adult patients, including patients at increased risk for severe RSV
- Review the most recent efficacy and safety data on FDA-approved RSV vaccines
- Identify underlying causes of vaccine fatigue and vaccine hesitancy
Faculty
Mary Koslap-Petraco DNP, PPCNP-BC, CPNP, FAANP
Adjunct Clinical Assistant Professor
Stony Brook University School of Nursing
Stony Brook, New York
Course Details
FREECME2025-07-22
Accreditations
This course is being provided by a Relias LLC strategic partner. Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.